West Family Investments Inc. Has $437,000 Holdings in Sanofi $SNY

West Family Investments Inc. increased its holdings in Sanofi (NASDAQ:SNY) by 52.2% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 9,052 shares of the company’s stock after purchasing an additional 3,105 shares during the period. West Family Investments Inc.’s holdings in Sanofi were worth $437,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in SNY. Capital Analysts LLC boosted its holdings in shares of Sanofi by 14.0% during the 1st quarter. Capital Analysts LLC now owns 1,664 shares of the company’s stock worth $92,000 after buying an additional 204 shares during the period. Thomasville National Bank lifted its position in Sanofi by 0.3% during the 2nd quarter. Thomasville National Bank now owns 80,440 shares of the company’s stock worth $3,886,000 after acquiring an additional 211 shares during the last quarter. CreativeOne Wealth LLC boosted its holdings in Sanofi by 2.8% during the second quarter. CreativeOne Wealth LLC now owns 8,980 shares of the company’s stock valued at $434,000 after acquiring an additional 241 shares during the period. U.S. Capital Wealth Advisors LLC grew its position in shares of Sanofi by 4.1% in the second quarter. U.S. Capital Wealth Advisors LLC now owns 6,227 shares of the company’s stock valued at $301,000 after purchasing an additional 247 shares during the last quarter. Finally, Whipplewood Advisors LLC grew its position in shares of Sanofi by 18.2% in the second quarter. Whipplewood Advisors LLC now owns 1,606 shares of the company’s stock valued at $78,000 after purchasing an additional 247 shares during the last quarter. 14.03% of the stock is owned by institutional investors.

Sanofi Stock Down 0.4%

Shares of SNY opened at $49.85 on Friday. The business’s 50 day simple moving average is $49.56 and its 200-day simple moving average is $49.24. Sanofi has a one year low of $44.62 and a one year high of $60.12. The company has a market capitalization of $122.41 billion, a P/E ratio of 11.67, a PEG ratio of 1.38 and a beta of 0.49. The company has a debt-to-equity ratio of 0.16, a current ratio of 1.06 and a quick ratio of 0.94.

Sanofi (NASDAQ:SNY) last announced its earnings results on Friday, October 24th. The company reported $2.91 earnings per share for the quarter, topping analysts’ consensus estimates of $1.60 by $1.31. Sanofi had a net margin of 21.96% and a return on equity of 12.70%. The company had revenue of $15.46 billion during the quarter, compared to the consensus estimate of $12.62 billion. During the same period in the previous year, the firm posted $2.25 earnings per share. The company’s revenue was down 7.5% on a year-over-year basis. As a group, sell-side analysts predict that Sanofi will post 4.36 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts recently commented on the stock. Deutsche Bank Aktiengesellschaft upgraded Sanofi from a “hold” rating to a “buy” rating in a research note on Tuesday, September 2nd. Jefferies Financial Group reissued a “buy” rating on shares of Sanofi in a report on Monday, October 27th. JPMorgan Chase & Co. upgraded Sanofi from a “neutral” rating to an “overweight” rating in a research note on Friday, August 8th. Morgan Stanley raised Sanofi from an “equal weight” rating to an “overweight” rating and raised their target price for the stock from $56.00 to $58.00 in a research report on Monday, September 8th. Finally, Wall Street Zen raised shares of Sanofi from a “hold” rating to a “buy” rating in a report on Saturday, August 2nd. Two investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $62.67.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.